Tectonic Therapeutic, Inc. announced that it plans to initiate its Phase 2 randomized, placebo-controlled, double-blind proof-of-concept clinical trial to evaluate TX45 in patients with Group 2 Pulmonary Hypertension (?PH?) in the setting of Heart Failure with Preserved Ejection Fraction (?HFpEF?) in the second half of 2024. The Phase 2 clinical trial is expected to be conducted globally, including at clinical trial sites in the United States, Europe, Eastern Europe and Australia. This trial is designed to enrich for patients with an increased pulmonary vascular resistance of greater than 3 on baseline right heart catheterization with the goal of evaluating efficacy in both Combined pre-and post-capillary Pulmonary Hypertension as well as the whole Group 2 PH population with HFpEF.

The Company currently expects that approximately 180 subjects will enter the trial. Each subject will be randomized to one of two treatment arms or a placebo arm. The treatment period will last for 24 weeks and there will be a follow-up evaluation 8 weeks after the last dose.